Astellas Receives FDA Approval for Use of Prograf

The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf (tacrolimus) in conjunction with mycophenolate mofetil for the prevention of organ rejection in kidney transplant recipients.
RedOrbit